Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: hip fracture

Mediterranean Diet Tied to Lower Hip Fracture Risk

Andrew M. Seaman  |  March 29, 2016

(Reuters Health)—Women who maintain an overall healthy diet may benefit from a slightly reduced risk of hip fractures later in life, according to a new U.S. study. Women who followed a Mediterranean-style diet were about three tenths of a percent less likely to break a hip over about 16 years, compared to women who didn’t…

Filed under:ConditionsOsteoarthritis and Bone Disorders Tagged with:DieteatingFractureshiphip fracturehip fracture riskMediterranean dietOsteoporosis

Unexpected Benefits of Bisphosphonates after Hip Fracture

Cathleen Colon-Emeric, MD, MHS  |  February 3, 2012

Recent trials show this bisphosphonates can reduce subsequent hip fractures and mortality, while remaining cost effective.

Filed under:ConditionsOsteoarthritis and Bone Disorders Tagged with:anti-inflammatoryboneFractureship fractureOsteoporosispatient carerheumatologist

Fracture & an Aging World

Jason Liebowitz, MD, FACR  |  September 24, 2024

Insights into osteoporosis treatments as societies around the world age.

Filed under:ConditionsEULAR/OtherMeeting ReportsOsteoarthritis and Bone Disorders Tagged with:APLARAPLAR 2024Asia Pacific League of Associations for Rheumatology (APLAR)bisphosphonatesdenosumabdrug holidayOsteoporosisosteoporosis treatmentsromosozumabzoledronic acid

Case Report: Hip Pain in End-Stage Renal Disease

Ilana P. Goldberg, MD, & Samuel Faught, MD  |  September 8, 2024

Renal osteodystrophy is associated with chronic kidney disease (CKD) and its associated metabolic derangements, most commonly CKD stages 3–5. It is often subclassified into four histological subtypes, with definite distinctions unable to be made clinically. These four subtypes, which may only be differentiated by bone biopsy, include: osteitis fibrosa cystica, mixed uremic osteodystrophy, osteomalacia and…

Filed under:ConditionsOsteoarthritis and Bone DisordersOther Rheumatic Conditions Tagged with:case reportEnd-stage renal diseasehip painimagingJoint PainRenal diseaserenal osteodystrophy

Treat to Target Lowers the Risk of Fracture in Patients with Gout

Arthritis & Rheumatology  |  July 26, 2023

Using data from the U.K.’s Health Improvement Network, a primary care database, Wei et al. examined whether urate-lowering therapy (ULT) in a treat-to-target approach for patients with gout reduces the risk of fracture.

Filed under:ConditionsGout and Crystalline Arthritis Tagged with:Arthritis & Rheumatologyfracture riskFracturesGoutGout Resource CenterResearchserum urate levels

Supplemental Vitamin D May Not Protect Against Fractures in Healthy Adults

Lara C. Pullen, PhD  |  March 2, 2023

Supplemental vitamin D may not significantly lower the risk of fractures in generally healthy adults compared with placebo, according to a large study by LeBoff et al.

Filed under:Conditions Tagged with:fracture riskFracturesVitamin Dvitamin D supplementationVitamin D3

FDA Approves Abaloparatide to Treat Men with Osteoporosis & a High Risk of Fracture

Michele B. Kaufman, PharmD, BCGP  |  February 15, 2023

In late December, the FDA approved subcutaneous abaloparatide for the treatment of men with osteoporosis at a high risk of fracture. This approval is based on a placebo-controlled study that showed abaloparatide led to significant increases in bone mineral density of the lumbar spine, total hip and femoral neck. Abaloparatide was approved in April 2017 for the treatment of postmenopausal women with osteoporosis at high risk for fracture.

Filed under:ConditionsDrug UpdatesOsteoarthritis and Bone Disorders Tagged with:abaloparatideFDAFDA approvalOsteoporosisosteoporosis treatmentsU.S. Food and Drug Administration (FDA)

At Least 1 Year on Bisphosphonates Needed for Fracture Prevention

Lisa Rapaport  |  December 14, 2021

(Reuters Health)—It takes 12.4 months of bisphosphonate therapy to prevent one nonvertebral fracture per 100 postmenopausal women with osteoporosis, a meta-analysis of randomized clinical trials suggests.1 Researchers examined data on 10 randomized clinical trials with a total of 23,384 women who had an osteoporosis diagnosis based on either existing vertebral fractures or a bone mineral…

Filed under:ConditionsOsteoarthritis and Bone Disorders Tagged with:bisphosphonatesfracture preventionFracturesOsteoporosispostmenopausal womenWomen

Denosumab Promising for Osteolysis after Total Hip Replacement

Marilynn Larkin  |  January 25, 2021

NEW YORK (Reuters Health)—Denosumab showed biological efficacy against osteolysis after total hip replacement in a proof-of-concept trial. “Denosumab is already a well-established licensed drug for the indications of osteoporosis and metastatic bone lesions in cancer, and has been shown to be effective in reducing erosions in inflammatory arthritis,” Dr. Mark J.M. Wilkinson of the University…

Filed under:Drug Updates Tagged with:denosumabtotal hip arthroplastytotal hip replacement

Targeted Vertebral Fracture Assessment

Lara C. Pullen, PhD  |  September 7, 2020

A Canadian study sought to identify individuals at high fracture risk and provide them with pharmacotherapy to prevent fractures. They found the assessment of hip and lumbar dual-energy X-ray absorptiometry scans for vertebral fracture can be useful in the identification of women and men aged 70 years and older who should qualify for anti-osteoporosis treatment…

Filed under:Uncategorized Tagged with:dual-energy X-ray absorptiometry (DXA)DXAFracture Risk Assessment ToolFracturesvertebral fracture

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 27
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences